Saama and Comprehend to Form Clinical Analytics Platform Company
Saama Technologies, Inc. has announced that it has signed a definitive agreement to acquire Comprehend Systems, Inc. This agreement combines Saama and Comprehend’s respective industry positions as clinical data analytics companies. Together, Saama and Comprehend will deploy and evolve their complementary clinical analytics platforms. This agreement creates an opportunity to increase their combined market share, as well as expand their existing partner ecosystems and deliver on a mutual commitment to accelerate clinical development towards unmet patient needs.
“The Comprehend-Saama transaction creates a data analytics powerhouse with a singular vision of improving human health through the application of AI-powered solutions for actionable clinical trial insights,” said Rick Morrison, Founder and Chairman of Comprehend. "The combined 30-plus years of experience of these two companies as data analytics innovators provides exciting opportunities to speed biopharma’s development of new therapeutics and to have broader industry reach.”
“Saama and Comprehend offer life sciences companies and patient-focused organizations the ability to access and optimize a combined ecosystem of unique, state-of-the-art analytics solutions and visualization tools that enable the re-imagination of clinical development and the realization of precision medicine,” said Rebecca Daniels Kush, Ph.D., founder of the Clinical Data Interchange Standards Consortium (CDISC), and member of Saama’s Clinical Board of Advisors.
Roche’s Susvimo Lands FDA Approval for Diabetic Retinopathy Based on Phase III Pavilion Trial Data
May 22nd 2025One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months achieved superior improvements on the Diabetic Retinopathy Severity Scale.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
